Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04940429 · ClinicalTrials.gov registry record
Eye Movement Testing in Patients With Obesity and the Impact of Weight Loss Surgery
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 19
- Enrollment target
NCT04940429: Clinical Trial study, sponsored by Stanford University.
NCT04940429 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04940429 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Obesity is a condition of chronic low-grade inflammation, thought to be secondary to adipose tissue secretion of cytokines including interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF- α) which effect multiple pathways and lead to an increase in C-reactive protein (CRP), a sensitive marker of systemic inflammation. Chronic inflammation is thought to be a major risk factor for the development of metabolic syndrome, diabetes, cardiovascular disease and cancer. Inflammatory cytokines have also been shown to directly and indirectly interact with the central nervous system influencing behavior and neural activity. Obesity is an independent risk factor for reduced cognitive function including poor attention, executive function and memory. Demonstrating improvement in dynamic visual processing following bariatric surgery could expand our understanding of the impact of obesity on central nervous system (CNS) function.
Primary Outcome
Composite oculometric testing score on Neurofit
Interventions
- DEVICE Neurofit
- DIAGNOSTIC_TEST Psychometric hepatic encephalopathy score
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2021-06-17 |
Why NCT04940429 stopped before completion
NCT04940429 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Neurofit is the first listed.
NCT04940429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04940429 about?
NCT04940429 is a clinical study titled "Eye Movement Testing in Patients With Obesity and the Impact of Weight Loss Surgery". Obesity is a condition of chronic low-grade inflammation, thought to be secondary to adipose tissue secretion of cytokines including interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF- α) which effect multiple pathways and lead to an increase in C-reactive protein (CRP), a sensitive marker o...
What is the current status of trial NCT04940429?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2018-11-27. Estimated completion is 2021-06-17.
What interventions are being tested in trial NCT04940429?
The interventions under investigation include: Neurofit (DEVICE), Psychometric hepatic encephalopathy score (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04940429?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI